India Glycols Limited has successfully demerged into three separate entities: India Glycols Limited, IGL Spirits Limited, and Ennature Bio Pharma Limited, effective September 1, 2026. Shareholders will receive shares in each new entity based on their holdings as of the record date, September 2, 2026. This strategic move aims to create focused businesses with dedicated management oversight and efficient capital allocation for each segment.
India Glycols Limited Completes Demerger
India Glycols Limited announced today that its demerger into three distinct entities is now effective as of September 1, 2026. The original company will now operate as three separate, publicly traded companies: the continuing India Glycols Limited, IGL Spirits Limited, and Ennature Bio Pharma Limited. This significant corporate restructuring was sanctioned by the Hon’ble National Company Law Tribunal, Allahabad Bench, and all necessary filings have been made with the Registrar of Companies.
Shareholder Entitlements
The demerger means that shareholders of India Glycols Limited as of the record date, September 2, 2026, will be entitled to receive shares in the newly formed companies. Specifically, shareholders will receive one equity share of IGL Spirits Limited for every one equity share held in India Glycols Limited. Additionally, they will receive one equity share of Ennature Bio Pharma Limited for every three equity shares held in India Glycols Limited. For example, a shareholder holding 300 shares of India Glycols Limited will receive 300 shares of IGL Spirits Limited and 100 shares of Ennature Bio Pharma Limited.
Business Segments and Focus
The original India Glycols Limited will continue to house its established businesses in chemicals, glycols, bio-glycols, new specialty products, and industrial gases. IGL Spirits Limited will focus on the spirits business, including IMFL, country liquor, and bio-fuel operations. Ennature Bio Pharma Limited will concentrate on the bio-pharma and bio-polymers businesses. This separation is expected to enable each company to have a dedicated business focus, enhancing management oversight and resource allocation towards growth.
Financial Performance of New Entities (June 2026 Quarter)
Preliminary financial performance for the June 2026 quarter indicates the potential of each entity: India Glycols Limited reported a net revenue of ₹345 crore, IGL Spirits Limited recorded net revenue of ₹694 crore, and Ennature Bio Pharma Limited generated a net revenue of ₹90 crore.
The management of IGL Spirits Limited and Ennature Bio Pharma Limited will apply for listing of their shares on the respective stock exchanges, while India Glycols Limited remains listed on both BSE and NSE.
Source: BSE
